Condition: AMD · Age-Related Macular Degeneration · Sponsor: VisionCare, Inc.
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD). Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.
This description comes directly from the study's public registry record.
Anne Roller, PhD · + 33 (0)3 88 30 88 11 · clinicals@medevise-consulting.com
Always discuss trial participation with your own doctor first.
| UZ Brussel | Brussels, Belgium | Recruiting |
| Centre d'Ophtalmologie Paradis-Monticelli | Marseille, France | Recruiting |
| Hélios Ophtalmologie, Saint-Jean-de-Luz | Saint-Jean-de-Luz, France | Recruiting |
| CHRU de Strasbourg | Strasbourg, France | Recruiting |
| Augenklinik Städtisches Klinikum Karlsruhe | Karlsruhe, Germany | Terminated |
| Universitätsklinikum Münster Klinik für Augenheilkunde | Münster, Germany | Recruiting |
| Mater Misericordiae University Hospital | Dublin, Ireland | Recruiting |
| Università degli Studi di Napoli Federico II | Naples, Italy | Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli | Roma, Italy | Recruiting |
| VISSUM | Alicante, Spain | Recruiting |
| Institut OMIQ | Barcelona, Spain | Recruiting |
| Hospital Universitario La Luz - Quirónsalud | Madrid, Spain | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04796545